DDInter1840 DDInter666
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eribulin
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is associated with {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Eribulin
Trabectedin {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Escitalopram
Escitalopram {u} may lead to a major life threatening interaction when taken with {v} Eribulin
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) regulates {v} (Gene) TUBB6
TUBB6 {u} (Gene) is bound by {v} (Compound) Eribulin
Trabectedin {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Verapamil
Verapamil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eribulin
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is upregulated by {v} (Compound) Pentamidine
Pentamidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eribulin
Trabectedin {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eribulin
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eribulin
Trabectedin {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Emtricitabine
Emtricitabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eribulin
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Eribulin
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is associated with breast cancer (Disease) and breast cancer (Disease) is treated by Eribulin (Compound)
Trabectedin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Escitalopram (Compound) and Escitalopram may lead to a major life threatening interaction when taken with Eribulin
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) regulates TUBB6 (Gene) and TUBB6 (Gene) is bound by Eribulin (Compound)
Trabectedin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Verapamil (Compound) and Verapamil may cause a minor interaction that can limit clinical effects when taken with Eribulin
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is upregulated by Pentamidine (Compound) and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Trabectedin (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Paclitaxel (Compound) and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Trabectedin (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Emtricitabine (Compound) and Emtricitabine may cause a minor interaction that can limit clinical effects when taken with Eribulin
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Crizotinib (Compound) and SRC (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Eribulin